Foreign And Domestic Firms See Eye-To-Eye In China’s Latest Innovation Proposal
This article was originally published in PharmAsia News
Multinationals and domestic pharma companies in China are joining forces to demand an innovation-enabling environment, underscored by faster regulatory reform, better market access and stronger intellectual property protection.
You may also be interested in...
Regardless of who wins, China seems to be looking beyond the 3 November US General Election, instead pouring in large resources to elevate its domestic health sector on a par with international standards, creating opportunities and profoundly impacting many areas from novel therapy development to investment decisions.
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.